Patent SG-11201906895W-A (SG)
Title: Rna cancer vaccines
Inventor: VALIANTE NICHOLAS
IPC: A61K39/39
Filed: 2017-10-26
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT D IVIIlOHIIOI0IIIDIDHOHOIIl1101 O II111110vOIIIIII (10) International Publication Number WO 2018/144082 Al (51) International Patent Classification: A61K 31/7088 (2006.01) A61K 39/39 (2006.01) A61P 35/00 (2006.01) A61K 31/7105 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/US2017/058595 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/453,444 01 February 2017 (01.02.2017) US 62/453,465 01 February 2017 (01.02.2017) US 62/558,238 13 September 2017 (13.09.2017) US (71) Applicant: MODERNATX, INC. [US/US]; 320 Bent Street, Cambridge, MA 02141 (US). (72) Inventors: VALIANTE, Nicholas; 70 Norfolk Street, Cambridge, MA 02139 (US). ASHBURN, Ted; 1688 Washington Street, No. 1, Boston, MA 02118 (US). HOPSON, Kristen; 331 Appleton Street, Arlington, MA 02476 (US). (74) Agent: LOCKHART, Helen, C. et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: RNA CANCER VACCINES RNA 1 /S1INFEKL 1500 Immunogenicity RNA 31 20 epitopes 21 flanks 20 epitopes_21 flank Class 11_15 flank Class I 52 epitopes_21 flanks 52 epitopes_21 flank Class 11_15 flank Class I 000 E72 Media RNA 31 1-1 C•1 GC O 71- 00 O 71- 1-1 1-1 C•1 C FIG. (57) : The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compo- sitions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response. [Continued on next page] WO 2018/144082 Al MIDEDIM31010101g0E1010MOIOHOHOIREEMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))